Corporate ActionJul 1, 2026, 06:11 AM
Encore Medical to Offer 3M Shares in IPO at $5.00 Each
AI Summary
Encore Medical, Inc. filed an S-1/A for its initial public offering, proposing to sell 3,000,000 shares of common stock at an expected price of $5.00 per share, aiming to raise $15,000,000. The net proceeds, estimated at $12,600,000, will primarily fund clinical trials for stroke and migraine indications, debt repayment, and general corporate purposes. The company, which has incurred net losses, also recently licensed AI technology from GB Sciences, Inc. for $2.0 million cash and 1,000,000 shares, though its primary focus remains on septal occlusion technologies.
Key Highlights
- Proposed IPO of 3,000,000 common shares at $5.00 each.
- Expected gross proceeds of $15,000,000 from the IPO.
- Net proceeds of approximately $12,600,000 for clinical trials and debt repayment.
- Granted underwriters a 45-day option to purchase up to 450,000 additional shares.
- Licensed AI technology from GB Sciences for $2.0M cash and 1,000,000 shares.
- Reported a net loss of $278,915 for Q1 2026.
- Reported a net loss of $928,088 for the year ended December 31, 2025.
- Cash balance was $34,619 as of March 31, 2026.
Price Impact
More from EMI